Search | WHO COVID-19 Research Database

WHO COVID-19 Research Database

News/Update/Help

Advanced Search

The WHO Covid-19 Research Database is a resource created in response to the Public Health Emergency of International Concern (PHEIC). Its content remains searchable and spans the time period March 2020 to June 2023. Since June 2023, manual updates to the database have been discontinued.

Show: 20 | 50 | 100

Results 1 - 1 de 1

Filter

Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.

Corominas, Hèctor; Castellví, Ivan; Diaz-Torné, César; Matas, Laia; de la Rosa, David; Mangues, Maria Antònia; Moya, Patricia; Pomar, Virginia; Benito, Natividad; Moga, Ester; Sosa, Nerea Hernandez-de; Casademont, Jordi; Domingo, Pere.

Medicine (Baltimore) ; 100(19): e25923, 2021 May 14.

Article in English | MEDLINE | ID: covidwho-1455404

ABSTRACT

ABSTRACT: Blocking IL-6 pathways with sarilumab, a fully human anti-IL-6R antagonist may potentially curb the inflammatory storm of SARS-CoV2. In the present emergency scenario, we used "off-label" sarilumab in 5 elderly patients in life-threatening condition not candidates to further active measures. We suggest that sarilumab can modulate severe COVID-19-associated Cytokine Release Syndrome.

Subject(s)

Antibodies, Monoclonal, Humanized/therapeutic use , COVID-19 Drug Treatment , Cytokine Release Syndrome/drug therapy , Interleukin-6/antagonists & inhibitors , Aged , Anti-Infective Agents/therapeutic use , Azithromycin/therapeutic use , COVID-19/physiopathology , Comorbidity , Critical Illness , Cytokine Release Syndrome/physiopathology , Humans , Hydroxychloroquine/therapeutic use , Male , Middle Aged , RNA, Viral , Respiration, Artificial/statistics & numerical data , Retrospective Studies , SARS-CoV-2

ABSTRACT

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL